Imo J Akpan1, Brady Lee Stein2. 1. Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, 676 N. St. Clair Street, Suite 21-100, Chicago, IL, 60611, USA. 2. Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, 645 N. Michigan Avenue, Suite 1020, Chicago, IL, 60611, USA. bstein@nm.org.
Abstract
PURPOSE OF REVIEW: To review the epidemiology, diagnostic challenges, pathogenesis, and treatment strategies for patients with myeloproliferative neoplasm-associated splanchnic vein thrombosis. RECENT FINDINGS: The epidemiology of myeloproliferative neoplasm-associated splanchnic vein thrombosis (MPN-SVT) has been well characterized. While typical MPN-associated thrombosis affects older patients and involves the arterial circulation, MPN-SVT mostly impacts younger women. An association with JAK2 V617F is well-known; recent studies have demonstrated only a weak association with CALR mutations. JAK inhibition may represent a novel treatment strategy, complementing anticoagulation, and management of portal hypertension. While the epidemiology has been well characterized, more work is needed to identify novel contributors to disease pathogenesis, beyond the JAK2 V617F mutation itself, and endothelial compromise. Testing for MPN mutations in the setting of non-cirrhotic SVT is commonplace; JAK2 V617F is the most likely to be identified. Testing for CALR or MPL mutations requires clinical judgement, though not unreasonable. The mainstay of therapy is indefinite anticoagulation; the role of direct oral anticoagulants is unclear. JAK inhibition may play a role in addressing associated splenomegaly and portal hypertension.
PURPOSE OF REVIEW: To review the epidemiology, diagnostic challenges, pathogenesis, and treatment strategies for patients with myeloproliferative neoplasm-associated splanchnic vein thrombosis. RECENT FINDINGS: The epidemiology of myeloproliferative neoplasm-associated splanchnic vein thrombosis (MPN-SVT) has been well characterized. While typical MPN-associated thrombosis affects older patients and involves the arterial circulation, MPN-SVT mostly impacts younger women. An association with JAK2 V617F is well-known; recent studies have demonstrated only a weak association with CALR mutations. JAK inhibition may represent a novel treatment strategy, complementing anticoagulation, and management of portal hypertension. While the epidemiology has been well characterized, more work is needed to identify novel contributors to disease pathogenesis, beyond the JAK2 V617F mutation itself, and endothelial compromise. Testing for MPN mutations in the setting of non-cirrhotic SVT is commonplace; JAK2 V617F is the most likely to be identified. Testing for CALR or MPL mutations requires clinical judgement, though not unreasonable. The mainstay of therapy is indefinite anticoagulation; the role of direct oral anticoagulants is unclear. JAK inhibition may play a role in addressing associated splenomegaly and portal hypertension.
Authors: Brady L Stein; Santosh Saraf; Urszula Sobol; Anna Halpern; Jamile Shammo; Damiano Rondelli; Laura Michaelis; Olatoyosi Odenike; Alfred Rademaker; Anaadriana Zakarija; Brandon McMahon; Jerry L Spivak; Alison R Moliterno Journal: Leuk Lymphoma Date: 2013-01-08
Authors: Dawid T Janczak; Malgorzata K Mimier; Robert D McBane; Patrick S Kamath; Benjamin S Simmons; Dalene M Bott-Kitslaar; Charles J Lenz; Emily R Vargas; David O Hodge; Waldemar E Wysokinski Journal: Mayo Clin Proc Date: 2017-12-06 Impact factor: 7.616
Authors: Malin Hultcrantz; Magnus Björkholm; Paul W Dickman; Ola Landgren; Åsa R Derolf; Sigurdur Y Kristinsson; Therese M L Andersson Journal: Ann Intern Med Date: 2018-01-16 Impact factor: 25.391